Elanco Animal Health Incorporated has secured U.S. Department of Agriculture (USDA) approval for Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody injection designed to treat canine allergic and atopic dermatitis. The product joins a rapidly expanding dermatology portfolio and marks the company’s second such approval in less than 18 months. Befrena offers dosing every 6 to 8 weeks, and Elanco expects to launch the product commercially in the first half of 2026

What this approval adds to Elanco’s dermatology pipeline strategy

The USDA approval of Befrena signals a deeper strategic move by Elanco Animal Health to solidify its presence in the $1.3 billion U.S. canine dermatology market. While the company is already competing with Zenrelia (ilunocitinib tablets)—a daily oral JAK inhibitor—Befrena introduces a long-acting biologic alternative in a category still dominated by lokivetmab, the active ingredient in Zoetis’ blockbuster product Cytopoint.

Elanco’s positioning with Befrena reflects a direct challenge to Zoetis’ first-mover advantage. Cytopoint, the market leader, is typically administered every 4 to 8 weeks. Elanco is keen to differentiate by offering veterinarians a treatment window of 6 to 8 weeks, subtly emphasizing longer-lasting effects while maintaining flexibility.

What stands out most, however, is Elanco’s dual-path strategy: combining the small molecule approach of Zenrelia with the biologic modality of Befrena. This mirrors human dermatology playbooks, where companies offer both fast-acting oral agents and longer-term antibody-based maintenance options. Industry observers note that such portfolio breadth may increase formulary presence and veterinarian preference—especially in practices treating large itchy-dog populations year-round.

Why IL-31 remains a validated and competitive target

Interleukin-31 (IL-31) remains a validated cytokine target in both human and animal dermatology. In dogs, IL-31 has been strongly implicated in the pathophysiology of allergic and atopic dermatitis, driving pruritus (itching) and inflammation. Both lokivetmab and tirnovetmab are monoclonal antibodies targeting this cytokine, meaning Befrena does not introduce a fundamentally novel mechanism but competes on pharmacokinetics, tolerability, and label flexibility.

For clinicians, this means Befrena is unlikely to displace Cytopoint based on mechanism alone. The commercial challenge lies in demonstrating either superior durability, improved side effect profiles, or meaningful differentiation on pricing, formulation, or availability. While the company did not disclose comparative efficacy data or direct head-to-head trials, the approval signals that efficacy was sufficient by USDA standards, which focus on safety, purity, and potency in veterinary biologics.

Veterinary dermatologists tracking the field suggest that having another IL-31–targeting agent could ease product shortages or supply chain disruptions that have periodically affected access to existing treatments. But from a scientific standpoint, it remains to be seen whether tirnovetmab will meaningfully shift clinical practice or merely expand the number of available biologics in an already consolidated market.

What this reveals about regulatory preferences and market gaps

USDA approval of monoclonal antibodies—rather than U.S. Food and Drug Administration (FDA) clearance—continues to reflect the bifurcated nature of veterinary drug regulation in the United States. While small molecules like Zenrelia require FDA approval, biologics such as Befrena fall under USDA jurisdiction, which uses different criteria for approval, notably avoiding traditional clinical trial endpoints.

This regulatory split allows companies like Elanco to accelerate market entry for antibody products, often with less stringent trial requirements. However, it also complicates comparative effectiveness assessments for clinicians. Because USDA-approved mAbs don’t typically publish full clinical trial datasets, veterinarians may have limited visibility into the design, population characteristics, or duration of response metrics—factors that are standard in FDA-reviewed products.

The industry has long debated whether this dual-path regulatory structure serves pet health optimally. With the increasing sophistication of biologics and the growing demand from pet owners for human-grade data transparency, there may be mounting pressure on companies to voluntarily disclose more clinical evidence, especially as pricing moves toward parity with human therapeutic benchmarks.

How Elanco is leveraging real-world itch data to shape adoption

Elanco is framing the Befrena launch within a broader narrative around the high burden of pruritus in the U.S. canine population. Its proprietary “America’s Itchy Dogs Report,” cited in the announcement, presents a marketing-forward but insight-rich foundation for understanding unmet need. According to Elanco’s internal data, 9 out of 10 dogs reportedly suffer from itching symptoms annually, yet owners often delay veterinary consultation by up to six weeks—spending an average of $400 on over-the-counter products before seeking professional help

This timeline of delayed care translates into more severe skin conditions and higher treatment costs. By positioning Befrena as a longer-lasting, injectable option that requires less owner compliance and has minimal behavioral disruption to dogs, Elanco aims to intercept these cases earlier and potentially reduce overall cost of care.

Whether this framing will shift owner behavior is unclear, but the data does suggest a genuine demand for longer-lasting, easy-to-administer dermatologic interventions that can break the cycle of delay and deterioration. Elanco is betting that Befrena’s once-every-two-month regimen could find favor with time-constrained owners and busy clinics alike.

What remains uncertain for Befrena’s market rollout

Elanco has not disclosed expected pricing, nor has it outlined manufacturing scale-up plans, vial sizes, or cold chain logistics—all of which are crucial in determining Befrena’s ability to compete with Cytopoint, which already benefits from significant distribution depth and brand loyalty.

Another area of uncertainty is reimbursement. While most veterinary biologics are out-of-pocket purchases, larger practices or pet insurance carriers may seek clarity on cost-effectiveness, especially for chronic users. If Elanco prices Befrena aggressively, it could carve out share among price-sensitive clinics. But if positioned as a premium product, it may only capture the upper end of the market unless backed by compelling real-world outcome data.

The label also does not yet address combination use with other dermatology agents, such as corticosteroids or JAK inhibitors. Given that Zenrelia remains under Boxed Warning constraints related to vaccine response, clinicians may hesitate to layer therapies without clearer guidance. Additional safety data—especially in puppies, breeding dogs, or immunocompromised animals—would help address these gaps.

What to watch next as Befrena approaches launch

With a first-half 2026 launch timeline, Elanco is likely entering a crucial year of education, inventory planning, and key opinion leader engagement. Several signals will be important in tracking Befrena’s early trajectory:

How many veterinary dermatology practices adopt it within six months of launch? What incentives or sampling strategies does Elanco employ? Will the company invest in comparative outcome studies, or rely solely on anecdotal field reports?

Another key unknown is whether Elanco will pursue international approvals for Befrena in Europe, Asia, or Latin America, following the same geographic pattern as Zenrelia. Global uptake could accelerate monoclonal antibody penetration in veterinary medicine more broadly, pushing rivals to innovate beyond IL-31 or introduce biosimilar strategies.

Finally, with the competitive landscape likely to intensify, Elanco’s success with Befrena may influence how aggressively other animal health players develop next-generation dermatologic antibodies. The company’s dual-modality strategy with Zenrelia and Befrena could become a blueprint—or a cautionary tale—depending on how the market responds.

  Befrena, biologics, canine allergic dermatitis, canine atopic dermatitis, Cytopoint, Elanco Animal Health, IL-31, tirnovetmab, veterinary dermatology, veterinary monoclonal antibody, Zenrelia